Compare Repligen Corporation Common Stock (RGEN) vs Teradyne, Inc. (TER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Teradyne, Inc. — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.31B), while Teradyne, Inc. trades at $348.8 (market cap $56.20B). The key difference: Teradyne, Inc. is far larger — about 5× Repligen Corporation Common Stock's market cap, and Teradyne, Inc. pays a 0.14% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Teradyne, Inc. for 37 Days on average.
| RGEN | TER | |
|---|---|---|
Market Cap | $11.31B | $56.20B |
Volume | 1,216,919 | 3,754,298 |
Sector | Health | Technology |
52-Week High | $194.57 | $483.84 |
52-Week Low | $102.87 | $138.09 |
Typical Hold Time | 0 Days | 37 Days |
Enterprise Value | $11.20B | $55.94B |
Dividend Yield | — | 0.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Teradyne (TER) trades at $380.29, down 0.93% on the day, with a bearish technical signal and support near $378. The stock shows strong fundamentals, beating earnings estimates in recent quarters, with a 25.77% net income margin and robust ROE of 36.66%. Recent news highlights expansion in AI-driven memory test solutions and strategic partnerships, positioning the company for growth in semiconductor equipment demand.
Outlook is positive with analyst consensus price target of $461.50, implying 21% upside, supported by 61% buy ratings. Risks include competitive pressures in semiconductor testing and reliance on cyclical tech spending. Earnings momentum and AI-driven demand present opportunities, but investors should monitor execution against high valuation multiples like a P/E of 52.24.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
